

POLYCYSTIC OVARY SYNDROME (PCOS): ENDOCRINE BASIS AND TREATMENT STRATEGIES

Barnoxonim Yuldasheva

Alfraganus University, Faculty of Medicine

4th-year Medical Student, Clinical Internship

*Scientific Advisor: **Rahmatullayeva Aziza Farxodovna***

Gynecologist, Pediatric Gynecologist

Abstract: *Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. The syndrome involves complex interactions between the hypothalamic-pituitary-ovarian axis, insulin resistance, and metabolic dysregulation. PCOS is associated with reproductive complications such as infertility, menstrual irregularities, and increased risk of pregnancy-related complications, as well as long-term metabolic and cardiovascular risks. This article reviews the endocrine mechanisms underlying PCOS and explores current therapeutic strategies, including lifestyle interventions, pharmacological treatments, and assisted reproductive technologies, emphasizing individualized care to optimize reproductive and metabolic outcomes.*

Keywords: *Polycystic Ovary Syndrome, PCOS, endocrine dysfunction, hyperandrogenism, insulin resistance, reproductive health, ovulatory dysfunction, metabolic risk, treatment strategies*

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine disorder affecting approximately 6–20% of women of reproductive age worldwide, depending on diagnostic criteria. It is characterized by a combination of hyperandrogenism, chronic anovulation, and polycystic ovarian morphology, often accompanied by metabolic abnormalities such as insulin resistance, obesity, and dyslipidemia. The etiology of PCOS is multifactorial, involving genetic predisposition, environmental influences, and neuroendocrine dysregulation.

At the core of PCOS pathophysiology is the disruption of the hypothalamic-pituitary-ovarian (HPO) axis. Altered gonadotropin secretion, particularly increased luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), contributes to abnormal follicular development and excessive androgen production by the ovaries. Insulin resistance and compensatory hyperinsulinemia further exacerbate hyperandrogenism by stimulating ovarian androgen synthesis and reducing hepatic sex hormone-binding globulin (SHBG) levels.

The clinical manifestations of PCOS are diverse, ranging from menstrual irregularities and hirsutism to infertility and metabolic disorders. These features not

only impact reproductive health but also carry long-term risks for type 2 diabetes, cardiovascular disease, and endometrial hyperplasia. Early diagnosis and a comprehensive understanding of the underlying endocrine mechanisms are crucial for effective management.

Therapeutic strategies for PCOS aim to address both reproductive and metabolic aspects of the disorder. Lifestyle interventions, including diet, exercise, and weight management, form the cornerstone of treatment. Pharmacological options such as combined oral contraceptives, anti-androgen agents, insulin sensitizers, and ovulation-inducing medications are used depending on the patient's primary concerns, whether menstrual regulation, hirsutism, or fertility. For women with infertility, assisted reproductive technologies (ART) offer additional options to achieve pregnancy.

Understanding the complex interplay between endocrine dysfunction, metabolic abnormalities, and reproductive challenges is essential for individualized care in PCOS. Tailored treatment approaches can optimize menstrual regularity, improve fertility outcomes, and reduce long-term health risks, ultimately enhancing quality of life for affected women.

Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder characterized by the interplay of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Central to its pathophysiology is the dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis. Women with PCOS often exhibit increased frequency of gonadotropin-releasing hormone (GnRH) pulses, which leads to preferential secretion of luteinizing hormone (LH) over follicle-stimulating hormone (FSH). This imbalance promotes excessive androgen production by the ovarian theca cells and impairs normal follicular maturation, resulting in chronic anovulation and the formation of multiple cystic follicles within the ovary.

Hyperandrogenism manifests clinically as hirsutism, acne, alopecia, and, in some cases, virilization. Biochemically, elevated serum testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS) are commonly observed. Insulin resistance, present in approximately 50–70% of women with PCOS, plays a significant role in the pathogenesis of hyperandrogenism. Hyperinsulinemia directly stimulates ovarian androgen synthesis and suppresses hepatic production of sex hormone-binding globulin (SHBG), thereby increasing circulating free androgens. These metabolic disturbances also contribute to an elevated risk of obesity, dyslipidemia, impaired glucose tolerance, and type 2 diabetes mellitus.

Reproductive complications in PCOS include menstrual irregularities, oligo-ovulation or anovulation, and infertility. Chronic anovulation leads to unopposed estrogen exposure, which increases the risk of endometrial hyperplasia and, if untreated, may progress to endometrial carcinoma. Women with PCOS often present with prolonged cycles or amenorrhea, and infertility is a common indication for

clinical evaluation. Polycystic ovarian morphology is identified via ultrasound, typically demonstrating 12 or more follicles per ovary or increased ovarian volume.

Management of PCOS requires a multifaceted approach addressing both endocrine and metabolic abnormalities. Lifestyle modification, including caloric restriction, regular physical activity, and weight reduction, is the first-line intervention and has been shown to improve insulin sensitivity, reduce hyperandrogenism, and restore ovulatory cycles. Even modest weight loss of 5–10% can significantly enhance reproductive outcomes and reduce metabolic risk factors.

Pharmacological therapy is tailored to the patient's primary concerns. Combined oral contraceptives (COCs) are commonly prescribed to regulate menstrual cycles, reduce androgen-related symptoms, and provide endometrial protection. Anti-androgen agents such as spironolactone, flutamide, and finasteride are used to manage hirsutism and acne, often in combination with COCs to prevent pregnancy due to teratogenic potential. Insulin sensitizers, particularly metformin, improve insulin resistance, reduce androgen levels, and can restore ovulation, thereby benefiting both metabolic and reproductive outcomes.

For women seeking fertility, ovulation induction is the primary strategy. Clomiphene citrate, a selective estrogen receptor modulator, has traditionally been the first-line treatment, stimulating ovulation in many patients. Aromatase inhibitors, such as letrozole, have gained popularity due to higher ovulation and live birth rates compared to clomiphene. In cases of clomiphene-resistant PCOS, gonadotropin therapy or assisted reproductive technologies (ART), including in vitro fertilization (IVF), may be considered. Close monitoring is essential to minimize the risk of ovarian hyperstimulation and multiple gestations.

Long-term health risks in PCOS extend beyond reproductive age. Persistent insulin resistance, dyslipidemia, and obesity contribute to increased cardiovascular morbidity and mortality. Women with PCOS are also at higher risk for non-alcoholic fatty liver disease and metabolic syndrome. Regular screening for glucose intolerance, lipid abnormalities, and blood pressure is recommended. Endometrial protection through cyclic progestin therapy or the use of hormonal contraceptives is important to reduce the risk of hyperplasia and malignancy.

Emerging research highlights the role of low-grade chronic inflammation, adipokine dysregulation, and altered gut microbiota in the pathogenesis of PCOS. Understanding these mechanisms may lead to novel therapeutic approaches targeting metabolic and reproductive components simultaneously. Personalized treatment plans considering age, reproductive goals, metabolic profile, and symptom severity are essential for optimizing outcomes.

In addition to clinical management, patient education and psychosocial support are crucial. Women with PCOS often experience psychological distress, including depression, anxiety, and body image issues, related to hirsutism, obesity, and fertility

challenges. Multidisciplinary care, including endocrinologists, gynecologists, nutritionists, and mental health professionals, enhances treatment adherence and overall quality of life.

In summary, PCOS is a multifactorial endocrine disorder with significant reproductive and metabolic implications. Dysregulation of the HPO axis, hyperandrogenism, and insulin resistance form the core pathophysiology, manifesting in menstrual irregularities, infertility, and long-term metabolic risks. Management strategies encompass lifestyle modification, pharmacological therapy, ovulation induction, and, when necessary, assisted reproductive technologies. Early diagnosis, individualized treatment, and multidisciplinary care are critical to improving both reproductive and metabolic outcomes in women with PCOS.

Polycystic Ovary Syndrome (PCOS) is a multifactorial endocrine disorder with significant reproductive and metabolic implications. Dysregulation of the hypothalamic-pituitary-ovarian axis, hyperandrogenism, and insulin resistance form the core pathophysiology, manifesting in menstrual irregularities, infertility, and long-term metabolic risks. Management strategies encompass lifestyle modification, pharmacological therapy, ovulation induction, and, when necessary, assisted reproductive technologies. Early diagnosis, individualized treatment, and multidisciplinary care are critical to improving both reproductive and metabolic outcomes in women with PCOS. Effective management not only restores fertility and menstrual regularity but also reduces the risk of cardiovascular disease, type 2 diabetes, and endometrial complications, thereby enhancing overall quality of life.

References

1. Azziz, R., Carmina, E., Dewailly, D., et al. (2009). The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertility and Sterility*, 91(2), 456–488.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility*, 81(1), 19–25.
3. Teede, H. J., Misso, M. L., Costello, M. F., et al. (2018). International PCOS Guideline: 2018 update. *Human Reproduction*, 33(9), 1602–1618.
4. Moran, L. J., Misso, M. L., Wild, R. A., Norman, R. J. (2010). Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. *Human Reproduction Update*, 16(4), 347–363.
5. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al. (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism*, 98(12), 4565–4592.

6. Diamanti-Kandarakis, E., Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocrine Reviews*, 33(6), 981–1030.

7. Palomba, S., Falbo, A., Zullo, F., Orio, F. (2015). Evidence-based and potential benefits of metformin in women with polycystic ovary syndrome. *Endocrine*, 48(2), 295–306.

8. Fauser, B. C., Tarlatzis, B. C., Rebar, R. W., et al. (2012). Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. *Human Reproduction*, 27(1), 14–24.

9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility*, 81(1), 19–25.

10. Nestler, J. E., Jakubowicz, D. J. (2001). Lean women with polycystic ovary syndrome respond to insulin reduction with metformin. *Diabetes Care*, 24(4), 619–622.